Cargando…

Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques

Pediatric SARS-CoV-2 vaccines are needed that elicit immunity directly in the airways, as well as systemically. Building on pediatric parainfluenza virus vaccines in clinical development, we generated a live-attenuated parainfluenza virus-vectored vaccine candidate expressing SARS-CoV-2 prefusion-st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nouën, Cyril Le, Nelson, Christine E., Liu, Xueqiao, Park, Hong-Su, Matsuoka, Yumiko, Luongo, Cindy, Santos, Celia, Yang, Lijuan, Herbert, Richard, Castens, Ashley, Moore, Ian N., Wilder-Kofie, Temeri, Moore, Rashida, Walker, April, Zhang, Peng, Lusso, Paolo, Johnson, Reed F., Garza, Nicole L., Via, Laura E., Munir, Shirin, Barber, Daniel, Buchholz, Ursula J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164439/ https://www.ncbi.nlm.nih.gov/pubmed/35665011 http://dx.doi.org/10.1101/2022.05.21.492923

Ejemplares similares

Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys
por: Le Nouën, Cyril, et al.
Publicado: (2022)

Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques
por: Buchholz, Ursula, et al.
Publicado: (2023)

A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters
por: Liu, Xueqiao, et al.
Publicado: (2021)

Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters
por: Liu, Xueqiao, et al.
Publicado: (2023)

Defective positioning in granulomas but not lung-homing limits CD4 T cell interactions with Mycobacterium tuberculosis infected macrophages in rhesus macaques
por: Kauffman, Keith D., et al.
Publicado: (2017)

Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2
por: Park, Hong-Su, et al.
Publicado: (2022)

Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates
por: Liu, Xueqiao, et al.
Publicado: (2020)

Effects of Human Respiratory Syncytial Virus, Metapneumovirus, Parainfluenza Virus 3 and Influenza Virus on CD4+ T Cell Activation by Dendritic Cells
por: Le Nouën, Cyril, et al.
Publicado: (2010)

Respiratory Syncytial Virus Interferon Antagonist NS1 Protein Suppresses and Skews the Human T Lymphocyte Response
por: Munir, Shirin, et al.
Publicado: (2011)

CSF and Blood Oxytocin Concentration Changes following Intranasal Delivery in Macaque
por: Dal Monte, Olga, et al.
Publicado: (2014)

Delayed Disease in Cynomolgus Macaques Exposed to Ebola Virus by an Intranasal Route
por: Johnston, Sara C., et al.
Publicado: (2021)

Epidemiology and seasonality of human parainfluenza serotypes 1‐3 in Australian children
por: Greiff, Daniel R. L., et al.
Publicado: (2021)

Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque
por: Alfson, Kendra J., et al.
Publicado: (2017)

Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques
por: Lee, M. R., et al.
Publicado: (2020)

Efficacy of a live intranasal vaccine against parainfluenza type 3 and bovine respiratory syncytial virus in young calves with maternally derived antibodies
por: Metcalfe, Lucy, et al.
Publicado: (2020)

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults
por: Scaggs Huang, Felicia, et al.
Publicado: (2020)

Rhabdomyolysis Associated with Parainfluenza Virus
por: Douvoyiannis, Miltiadis, et al.
Publicado: (2013)

The alpha-1 subunit of the Na(+),K(+)-ATPase (ATP1A1) is required for macropinocytic entry of respiratory syncytial virus (RSV) in human respiratory epithelial cells
por: Lingemann, Matthias, et al.
Publicado: (2019)

Intranasally Administered Antigen 85B Gene Vaccine in Non-Replicating Human Parainfluenza Type 2 Virus Vector Ameliorates Mouse Atopic Dermatitis
por: Kitagawa, Hiroshi, et al.
Publicado: (2013)

Intranasal parainfluenza virus type 5 (PIV5)–vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study
por: Spearman, Paul, et al.
Publicado: (2023)

Parainfluenza and corona viruses in a fallow deer (Dama dama) with fatal respiratory disease
por: Dastjerdi, Akbar, et al.
Publicado: (2022)

Characterization of Two Porcine Parainfluenza Virus 1 Isolates and Human Parainfluenza Virus 1 Infection in Weaned Nursery Pigs
por: Welch, Michael, et al.
Publicado: (2022)

Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge
por: Clark, Kimberly M., et al.
Publicado: (2011)

Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
por: Nuijten, Piet, et al.
Publicado: (2022)

A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice
por: Gingerich, Maria Cristina, et al.
Publicado: (2023)

Successful Control of Human Parainfluenza Type 3 Outbreak in a Level IV Neonatal Intensive Care Unit
por: Navalkele, Bhagyashri, et al.
Publicado: (2021)

Human Parainfluenza Type 4 Infections, Canada
por: Vachon, Marie-Louise, et al.
Publicado: (2006)

Seasonality and clinical impact of human parainfluenza viruses
por: Maykowski, Philip, et al.
Publicado: (2018)

Haemophilus parainfluenzae urethritis through orogenital transmission
por: Saxena, Ajit, et al.
Publicado: (2018)

Influenza and Parainfluenza Associated Pediatric ICU Morbidity
por: Hon, Kam Lun, et al.
Publicado: (2010)

Parainfluenza Bronchiolitis Mimicking Recurrent Lobar Pneumonia
por: Bhattar, Keshav, et al.
Publicado: (2022)

Optimization of the Codon Pair Usage of Human Respiratory Syncytial Virus Paradoxically Resulted in Reduced Viral Replication In Vivo and Reduced Immunogenicity
por: Le Nouën, Cyril, et al.
Publicado: (2020)

Epidemiology and Clinical Presentation of Parainfluenza Type 4 in Children: A 3-Year Comparative Study to Parainfluenza Types 1–3
por: Frost, Holly M., et al.
Publicado: (2014)

Evaluating a Parainfluenza Virus 5-Based Vaccine in a Host with Pre-Existing Immunity against Parainfluenza Virus 5
por: Chen, Zhenhai, et al.
Publicado: (2012)

T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1
por: Harris, Katherine M., et al.
Publicado: (2020)

Attenuation of Human Respiratory Viruses by Synonymous Genome Recoding
por: Le Nouën, Cyril, et al.
Publicado: (2019)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

Minimally invasive monitoring of CD4 T cells at multiple mucosal tissues after intranasal vaccination in rhesus macaques
por: Dorta-Estremera, Stephanie, et al.
Publicado: (2017)

Two Cases of Primary Human Parainfluenza Virus 1 Pneumonia in Which Bronchoalveolar Lavage Fluid Yielded Human Parainfluenza Virus 1
por: Ishiguro, Takashi, et al.
Publicado: (2019)

Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants
por: Beavis, Ashley C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_alda2cemllgi424hq09tucgmih